Potential for expanding indications and curability criteria of endoscopic resection for early gastric cancer in elderly patients: results from a Japanese multicenter prospective cohort study
Masau Sekiguchi,Haruhisa Suzuki,Kohei Takizawa,Toshiaki Hirasawa,Yoji Takeuchi,Kenji Ishido,Shu Hoteya,Tomonori Yano,Shinji Tanaka,Yosuke Toya,Masahiro Nakagawa,Takashi Toyonaga,Kenichi Takemura,Kingo Hirasawa,Mitsuru Matsuda,Hironori Yamamoto,Yosuke Tsuji,Satoru Hashimoto,Yuki Maeda,Tsuneo Oyama,Ryuta Takenaka,Yoshinobu Yamamoto,Taichi Shimazu,Hiroyuki Ono,Satoshi Tanabe,Hitoshi Kondo,Hiroyasu Iishi,Motoki Ninomiya,Ichiro Oda,J-WEB/EGC group
DOI: https://doi.org/10.1016/j.gie.2024.01.026
IF: 10.396
2024-01-01
Gastrointestinal Endoscopy
Abstract:BACKGROUND AND AIMS: Evidence for endoscopic resection (ER) in elderly patients with early gastric cancer (EGC) is limited. We assessed its clinical outcomes, and explored new indications and curability criteria.METHODS: We analyzed data from a Japanese multicenter prospective cohort study. Patients aged ≥75 years with EGC treated with ER were included. We classified "eCuraC-2 (corresponding to noncurative ER, defined in the Japanese gastric cancer treatment guidelines)" into "elderly-high (EL-H)" (>10% estimated metastatic risk) and "elderly-low (EL-L)" (≤10%).RESULTS: In total, 3,371 patients with 3,821 EGCs were included; endoscopic submucosal dissection (ESD) was the prominent treatment choice. Among them, 3,586 lesions met the guidelines' ER indications and 235 did not. The proportions of en bloc and R0 resections and perforations were 98.9%, 94.4%, and 0.8%, respectively, in EGCs within the indications. In EGCs beyond the indications, they were 99.5%, 85.4%, and 5.9%, respectively, for lesions diagnosed as ≤3 cm, and 96.0%, 64.0%, and 18.0% for those >3 cm. Curative ER ("eCuraA/B") and EL-L were observed in 83.6% and 6.2% of lesions within the indications, respectively, and in 44.2% and 16.8% of lesions <3 cm beyond the indications, respectively. The 5-year cumulative gastric cancer death rates following eCuraA/B and EL-H were 0.3% (95% CI, 0.2-0.6) and 3.5% (2.0-5.7), respectively. Following EL-L, the rate was 0.9% (0.2-3.5) even without subsequent treatment.CONCLUSIONS: Usefulness of ESD for elderly EGC patients was confirmed by their clinical outcomes. Lesions ≤3 cm and EL-L emerged as new ER indication and curability criterion, respectively.
gastroenterology & hepatology